UK markets closed
  • FTSE 100

    +14.25 (+0.20%)
  • FTSE 250

    +14.61 (+0.06%)
  • AIM

    -7.18 (-0.58%)

    -0.0049 (-0.41%)

    -0.0036 (-0.26%)

    -1,745.48 (-3.77%)
  • CMC Crypto 200

    -49.69 (-3.31%)
  • S&P 500

    -4.88 (-0.11%)
  • DOW

    +73.94 (+0.21%)

    +1.48 (+1.79%)

    +11.20 (+0.63%)
  • NIKKEI 225

    +96.27 (+0.34%)

    +109.40 (+0.42%)
  • DAX

    +70.42 (+0.46%)
  • CAC 40

    +47.52 (+0.71%)

Global Pharmaceuticals & Biopharmaceuticals Continuous Manufacturing Market Report 2021: Technological Advancements Coupled with Facility Expansions - Forecast to 2027

·4-min read

Dublin, Sept. 29, 2021 (GLOBE NEWSWIRE) -- The "Global Continuous Manufacturing Market In Pharmaceuticals & Biopharmaceuticals Size, Share & Trends Analysis Report by Therapeutics Type, by Application, by Formulation, by Mode, by Scale, by Product, and Segment Forecasts, 2021-2027" report has been added to's offering.

The global continuous manufacturing market in pharmaceuticals and biopharmaceuticals size is expected to reach USD 2.3 billion by 2027, expanding at a CAGR of 13.85%

Although batch manufacturing is the dominant mode of product development within the pharma and biopharma industry, the companies have begun shifting their focus toward continuous manufacturing (CM).

The key drivers for the transition from batch to continuous manufacturing include drug shortage, more stringent requirements for consistent quality, the need for reduced processing costs, and the demand for higher and improved productivity.

Regulatory authorities are increasingly supportive of this therapeutic development model. They are encouraging the adoption of CM through releasing drafts and guidelines.

Moreover, the presence of communities and organizations that are devoted to the commercialization of this market within the pharma and biopharma sector is driving the revenue. CCP Summit 2020 is one of such summits that is engaged in exploring scientific and technological advancements to address the technology challenges and accelerate upfront investment in the market.

In addition, the growing demand for biosimilars and an ever-increasing pressure for reducing drug development costs have driven the interest of biopharma players in this space.

With a plethora of research activities available on making individual unit operations continuous, studies are also conducted to explore the possibility of a continuous end-to-end development process. Ongoing research efforts in this area are anticipated to greatly favor the revenue growth in the coming years.

Based on mode, in-house pharmaceutical companies are anticipated to witness lucrative growth in the coming years owing to the shift of well-established pharma players toward the continuous manufacturing market.

On the basis of scale, the clinical and preclinical scale manufacturing segments collectively captured a significant revenue share in 2020 owing to the easy integration of systems and a high number of ongoing R&D activities.

North America led the global market in 2020. This is attributed to the presence of key technology developers as well as high R&D expenditure in drug development by the end-users in the U.S. Key players are implementing various strategies to strengthen their product offerings and offer diverse technologically advanced products to accelerate therapeutics development.

Continuous Manufacturing Market In Pharmaceuticals & Biopharmaceuticals Report Highlights

  • In terms of therapeutics type, the pharmaceutical/small molecules segment dominated the market in 2020 owing to high technology penetration in this segment. The biopharmaceutical/large molecules segment is anticipated to witness lucrative growth owing to increasing investment in facility expansion to integrate CM systems

  • On the basis of application, finished product manufacturing led the market in 2020 owing to the established use of CM in finished product development due to the commercial cost and time-saving advantages of technology

  • By formulation, solid formulation dominated the market in 2020 owing to the maximum adoption of CM methodologies in solid drug production

  • Based on mode, the contract segment led the market in 2020 due to the ongoing demand, coupled with the increasing popularity of contract services. The increasing investment in biosimilars production is expected to spur the use of CM technology within contract manufacturing organizations

  • By product, semi-continuous systems accounted for the maximum revenue share in 2020 owing to the increasing adoption of a hybrid model of manufacturing within small to medium-sized drug developers as well as major pharma companies

Industry Outlook

Regulatory Landscape

Penetration & Growth Prospect Mapping for Therapeutics Type, 2020

Market drivers analysis

  • Commercial advantages of continuous manufacturing over batch manufacturing

  • Favourable regulatory environment

  • Technological advancements coupled with facility expansions in the bioprocessing industry

Market restraint analysis

  • Presence of well-established infrastructure for batch manufacturing

  • High implementation cost

Market opportunities analysis

  • Rising pressure on drug developers to meet consumer's therapeutics demand

  • Expanding market in regions such as APAC and LATAM

Market challenge analysis

  • Challenges pertaining to continuous manufacturing

Market Analysis & Tools

  • Continuous Manufacturing Market in Pharmaceuticals & Biopharmaceuticals: SWOT Analysis; By Factor (Political & Legal, Economic and Technological)

  • Industry Porter's Analysis

COVID-19 Impact Analysis

Companies Mentioned

  • Thermo Fisher Scientific, Inc.

  • Danaher Corporation

  • Applikon Biotechnology

  • Sartorius Stedim Biotech

  • GEA Group aktiengesellschaft

  • Corning Incorporated

  • Merck KGaA

  • Glatt GmbH

  • Repligen corporation

  • Eppendorf AG

  • Electrolab Biotech Ltd.

  • Solesis medical

  • Scott equipment company

  • L.B. BOHLE (Korsch ag)

  • Lonza Group AG

  • 3M

  • Cellgenix GmbH

  • Boehringer Ingelheim International GmbH

  • Bio-Rad Laboratories, Inc.

  • Avantor, Inc.

  • Ajinomoto Bio-Pharma

  • GlaxoSmithKline

  • Continuus Pharmaceuticals

  • Arcinova

  • Amgen

For more information about this report visit

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting